Clinical Trials on Cystic Fibrosis Lung Disease in Austria

Total 2865 results

Arrowhead Pharmaceuticals

Terminated

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Cystic Fibrosis, Pulmonary

Australia, New Zealand
Respirion Pharmaceuticals Pty Ltd

Recruiting

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas Aeruginosa | Cystic Fibrosis Lung | Respiratory Infections, Recurrent, Chronic

United States, Australia
AOP Orphan Pharmaceuticals AG

Completed

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

Cystic Fibrosis

Austria
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Cystic Fibrosis (CF)

United States, Australia, Belgium, Hungary, Netherlands, New Zealand, Slovakia, United Kingdom
Indiana University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease (Early CF)

Cystic Fibrosis

United States, Australia
Monash University

Recruiting

PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (PFOX)

Fibrotic Interstitial Lung Disease

Australia
Endeavor Biomedicines, Inc.

Not yet recruiting

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Idiopathic Pulmonary Fibrosis | Progressive Fibrosing Interstitial Lung Disease | Progressive Pulmonary Fibrosis

United States, Switzerland, Canada, Australia, Austria, United Kingdom, Malaysia, Mexico, Germany, Ireland, Korea, Republic of
Flatley Discovery Lab LLC

Completed

A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants

Cystic Fibrosis

Australia
The Alfred

Unknown

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (CISTIC)

Cystic Fibrosis

Australia
Bayside Health

Unknown

Modified Release Posaconazole in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
The Alfred

Unknown

CPET in CF Patients With One G551D Mutation Taking VX770

Cystic Fibrosis

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark
Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
The University of Queensland
Telethon Kids Institute

Completed

Prevention of Bronchiectasis in Infants With Cystic Fibrosis (COMBATCF)

Bronchiectasis | Cystic Fibrosis

Australia, New Zealand
Krystal Biotech, Inc.
Novotech (Australia) Pty Limited

Withdrawn

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Cystic Fibrosis

Australia
The Alfred
Monash University

Recruiting

The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. (A-STEP)

Fibrosis | Lung Diseases | Pancreatic Diseases | Cystic Fibrosis | Genetic Diseases | Respiratory Diseases

Australia
AlgiPharma AS
AlgiPharma Australia Pty. Ltd.

Unknown

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
Medical University Innsbruck
Queen's University, Belfast; Cystic Fibrosis Foundation; European Cystic Fibrosis...

Active, not recruiting

COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF

Covid19 | Cystic Fibrosis

Austria
Pharmaxis

Completed

A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Cystic Fibrosis

Australia, New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Completed

Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation

Cystic Fibrosis

Australia
Dr. Christopher Lambers
Clinical Trials Coordination Centre, Medical University of Vienna

Withdrawn

Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Lung Transplant; Complications

Austria
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
AbbVie
VIVUS LLC; Cystic Fibrosis Foundation; Digestive Care, Inc.; Nestlé Health Science

Terminated

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Fibrosing Colonopathy

United States
Neovii Biotech

Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Bronchiectasis | Idiopathic Pulmonary Fibrosis | Cystic Fibrosis | Chronic Obstructive Pulmonary | Pulmonary Vascular Disease

United States, Australia, Austria, Canada
Pharmaxis

Completed

Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients (DPM-PK-102)

Cystic Fibrosis

Australia, United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Healthy Volunteer - Complete | Cystic Fibrosis - Complete

United States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Cystic Fibrosis

Israel, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Savara Inc.
INC Research Limited

Completed

Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Healthy | Cystic Fibrosis

Australia
Medical University of Vienna

Completed

Explorative Study on the Molecular Pathology of Lung Fibrosis by Combination of Clinical Assessment and System Biology

Pulmonary Fibrosis

Austria
Bayside Health
National Health and Medical Research Council, Australia; Monash University; Cystic...

Unknown

Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Gilead Sciences

Terminated

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Cystic Fibrosis

France, Germany, Spain, United Kingdom, Australia
Cystetic Medicines, Inc.
DevPro Biopharma

Recruiting

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People With Cystic Fibrosis (ABCI)

Cystic Fibrosis

Australia, New Zealand
AstraZeneca

Completed

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis (MAHALE)

Non-cystic Fibrosis Bronchiectasis

United States, Canada, Denmark, Germany, Italy, United Kingdom, Vietnam, China, Spain, Korea, Republic of, Argentina, Australia, Poland, Russian Federation, Philippines, India
University Hospital Muenster

Unknown

Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways (mucostaph)

Lung Diseases | Cystic Fibrosis | Lung Function Decreased | Staphylococcus Aureus Pneumonia

Germany, Austria
Bayside Health
The Alfred

Unknown

Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease

Asthma | Cystic Fibrosis | Bronchiolitis Obliterans | Lung Transplantation

Australia
Novartis Pharmaceuticals

Completed

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Pulmonary Infections | Pseudomonas Aeruginosa in Cystic Fibrosis

United States, Italy, Germany, France, Australia, Canada, Spain, Hungary, Mexico, Argentina
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, United Kingdom, France, Spain, Israel, Romania, Korea, Republic of, Australia, Canada, New Zealand, Hungary, Georgia, Former Serbia and Montenegro, Peru
Sydney Children's Hospitals Network
Children's Hospital Colorado; Women's and Children's Hospital, Adelaide; John... and other collaborators

Completed

Cystic Fibrosis - Insulin Deficiency, Early Action (CF-IDEA)

Diabetes | Cystic Fibrosis

Australia, United States
Endeavor Biomedicines, Inc.

Completed

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Idiopathic Pulmonary Fibrosis

Australia
siRNAgen Therapeutics Inc.

Active, not recruiting

The First-in-human Study of SRN-001 in Healthy Participants

Idiopathic Pulmonary Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Switzerland, Australia

Clinical Trials on Cystic Fibrosis Lung Disease in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations